PIK3CA and head and neck squamous cell carcinoma: Furthermore, the specific class I PI3K p110α catalytic subunit inhibitor Alpelisib, that just gained FDA approval for the treatment of breast cancer patients with mutations in PIK3CA [33], the gene coding for this protein, is under preclinical evaluation in HNSCC.